Semaglutide (CAS 910463-68-2) and Tirzepatide (CAS 2023788-19-2) are regulated peptide active pharmaceutical ingredients (APIs). This article is a compliance-first overview for professional buyers. It makes no therapeutic or medical claims and is not directed at consumers.
Who these materials are for
These APIs are supplied strictly as raw materials to licensed pharmaceutical manufacturers and for laboratory research use only. They are not for sale to consumers and not for unlicensed compounding. Regulatory status varies by country, and the buyer is responsible for holding the appropriate licences and for import/export compliance in their jurisdiction.
Documentation to expect
- Batch-specific COA with purity by HPLC and the method stated;
- MSDS/SDS for safe handling and transport;
- On request, additional analytical data (e.g. HPLC/MS) for qualification.
The buyer's responsibilities
- Confirm your licence status and the legal basis for purchase in your market before ordering.
- Ensure correct classification, import permits and customs documentation.
- Keep pharmaceutical/API sourcing entirely separate from cosmetic sourcing and marketing — never blend the two in consumer-facing claims.
How WYOO handles these
WYOO supplies Semaglutide and Tirzepatide as raw materials for licensed manufacturers and research use only, with COA and MSDS. We do not make efficacy claims and expect buyers to meet all licensing and import obligations. For cosmetic customers, we keep our peptide conversation strictly to cosmetic-grade actives.
If you are a licensed manufacturer, contact us to discuss documentation and compliance requirements.